On the same side: VISTA and its ligands interact in cis on the cell surface
Karina Smorodinsky-Atias1, Gil Wiseglass1, Alina Artyukhova1
1School of Neurobiology, Biochemistry and Biophysics, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Abstract:
VISTA, an essential immune checkpoint protein, regulates peripheral T-cell quiescence and tolerance. Despite its potential as a target for anti-tumor and autoimmune disease therapies, uncertainty regarding VISTA's binding mode and membrane orientation has hindered the development of these therapies. Contrary to the prevailing view, we found, using cell aggregation assays, that VISTA does not interact with its ligands in a trans (between-cell) manner. Using MST and flow cytometry, we showed that when in soluble form, VISTA binds to its ligands, suggesting that VISTA's membrane orientation restricts trans interactions. In contrast, split luciferase complementation assays demonstrated that membrane-tethered VISTA interacts with its ligands in a cis manner (i.e., on the same cell). Co-expression data analysis from the Cancer Genome Atlas showed a strong correlation between VISTA and its ligand, PSGL-1, consistent with our in vitro cis interaction data. We propose that VISTA's Ig domain bends toward the membrane in an orientation that prevents trans while enabling cis interactions. Our findings reveal VISTA's binding mechanism and suggest an intrinsic inhibition signaling pathway independent of additional cells. Importantly, our experimental framework provides a platform for identifying novel VISTA-targeted therapeutics.
Insights
VISTA, an immune checkpoint protein, binds ligands in cis (same cell), not trans (between cells). This discovery clarifies VISTA
Area of Science:
- Immunology
- Molecular Biology
- Cell Biology
Background:
- VISTA is a critical immune checkpoint protein regulating T-cell function and tolerance.
- Understanding VISTA's binding mechanism is crucial for developing anti-tumor and autoimmune therapies.
- Previous studies lacked clarity on VISTA's membrane orientation and ligand interaction mode.
Purpose of the Study:
- To elucidate the binding mode and membrane orientation of VISTA.
- To investigate whether VISTA interacts with its ligands in trans or cis.
- To provide a framework for developing novel VISTA-targeted therapeutics.
Main Methods:
- Cell aggregation assays to assess trans interactions.
- MicroScale Thermophoresis (MST) and flow cytometry for soluble VISTA binding.
- Split luciferase complementation assays for membrane-tethered VISTA interactions.
- Cancer Genome Atlas data analysis for co-expression patterns.
Main Results:
- VISTA does not interact with ligands in a trans manner.
- Soluble VISTA binds ligands, but membrane-bound VISTA's orientation restricts trans interactions.
- Membrane-tethered VISTA exhibits cis interactions with its ligands.
- Strong VISTA and PSGL-1 co-expression correlation observed in cancer data.
- VISTA's Ig domain likely orients towards the membrane, favoring cis interactions.
Conclusions:
- VISTA primarily interacts with its ligands in cis, on the same cell.
- This cis interaction suggests an intrinsic VISTA signaling pathway.
- The findings clarify VISTA's mechanism, enabling targeted therapeutic development.
- The study presents a novel experimental platform for VISTA drug discovery.
Related Concept Videos
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Ligand Binding Sites
Signal Transduction: Overview
Typically, signal transduction involves three...
Selectins
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...


